Clinical Trials

Status
Published

Recently Activated

SHOW MORE
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

Status Notes
Activation - Effective 12/15/20, 12:00 PM Pacific Time

All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
Research Committee(s)
Breast Cancer
Activated
12-15-2020
ClinicalTrials.gov Registry Number
04647916
Open
Accrual
0%
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Symptom Control and Quality of Life
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2001

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects

Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
II
Accrual
1%
SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Status Notes
Activation, Effective 9/23/2020, 2:00 pm eastern
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013
Open
Phase
I-II
Accrual
0%
SWOG Clinical Trial Number
S1905

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

Status Notes
This study is open to accrual effective August 17, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Leukemia
Lymphoma
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324